Compliance with Anemia Management Indicators Among Maintenance Hemodialysis Patients: A Clinical Audit from a Tertiary Center
DOI:
https://doi.org/10.53778/pjkd101340Keywords:
anemia, compliance, indicators, hemodialysis, clinical auditAbstract
Background Anemia is a major complication among patients with end-stage renal disease (ESRD) receiving maintenance hemodialysis (MHD). Effective management requires consistent adherence to guideline-recommended practices, including hemoglobin monitoring, iron assessment, and appropriate erythropoiesis-stimulating agent (ESA) titration. This audit aimed to evaluate compliance with key anemia management indicators in a tertiary hemodialysis unit.
Methods A cross-sectional clinical audit was conducted among 62 adult MHD patients at Evercare Hospital Dhaka. Data were collected using a structured checklist based on KDIGO 2021 anemia guidelines. Eight indicators were assessed: anemia screening, iron status documentation, correction of iron deficiency, post-ESA hemoglobin monitoring, maintenance of target hemoglobin, quarterly iron profile checks, ESA dose adjustments, and completion of patient education. Compliance levels were analyzed descriptively and compared across genders.
Results High compliance (82–100%) was observed in anemia screening, ESA dosing, post-ESA hemoglobin monitoring, and patient education. Hemoglobin maintenance within target ranges showed moderate adherence (62.9%). Iron documentation (35.5%) and quarterly iron monitoring (8.1%) demonstrated critically low compliance. Male patients achieved better hemoglobin control than females (80.8% vs. 50%). A strong positive correlation was found between appropriate ESA titration and hemoglobin stability.
Conclusion The audit identified strong adherence to ESA-related processes and patient education but highlighted major gaps in iron assessment and routine monitoring. Strengthening iron management practices is essential to optimize anemia outcomes in MHD patients. Targeted quality-improvement interventions are recommended to enhance overall compliance and align practice with international standards.
References
Babitt JL, Lin HY. Mechanisms of anemia in CKD. Journal of the American Society of Nephrology. 2012 Oct 1;23(10):1631-4.
Mikhail A, Brown C, Williams JA, Mathrani V, Shrivastava R, Evans J, Isaac H, Bhandari S. Renal association clinical practice guideline on Anaemia of Chronic Kidney Disease. BMC nephrology. 2017 Nov 30;18(1):345.
Pantopoulos K. Oral iron supplementation: new formulations, old questions. Haematologica. 2024;109(9):2790-2801. doi:10.3324/haematol.2024.284967.
De Simone E, Sciascia S, Fenoglio R, Oddone V, Barreca A, Roccatello D. Antiphospholipid syndrome and kidney involvement. Kidney and Blood Pressure Research. 2023 Dec 21;48(1):666-77.
Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group. KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int Suppl. 2012 Aug 22;2(4):279-335.
Badura K, Janc J, Wąsik J, Gnitecki S, Skwira S, Młynarska E, Rysz J, Franczyk B. Anemia of chronic kidney Disease—A narrative review of its pathophysiology, diagnosis, and management. Biomedicines. 2024 May 27;12(6):1191.
Sidossis LS, Kales SN. Textbook of lifestyle medicine. John Wiley & Sons; 2022 Jan 25.
Wang N, Zhang C. Recent advances in the management of diabetic kidney disease: slowing progression. International Journal of Molecular Sciences. 2024 Mar 7;25(6):3086.
Cerdá J, Mohan S, Garcia-Garcia G, Jha V, Samavedam S, Gowrishankar S, Bagga A, Chakravarthi R, Mehta R, Group C, Acute Disease Quality Initiative. Acute kidney injury recognition in low-and middle-income countries. Kidney international reports. 2017 Jul 1;2(4):530-43.
Ponce D, Balbi A. Acute kidney injury: risk factors and management challenges in low- and middle-income countries. Eur Med J Nephrol. 2020;8(1):62-69. https://doi.org/10.33590/emjnephrol/20-00026
Alam K, Hayat AH, Ullah A, Sulaiman SA, Ahmad W, Ooi GS, Ahmad WA. The prevalence and impact of clinical pharmacists’ intervention on drug-related problems in patients with chronic kidney disease. Cureus. 2024 Apr 30;16(4).
Shreewastav RK, Joshi BR, Yadav R, Katwal A, Shrestha S. Iron Profile and Status of Anemia with the Associated Factors in Chronic Kidney Disease Patients. Journal of Nepal Health Research Council. 2023 Sep 10;21(01):129-35.
Makmun A, Satirapoj B, Foo MW, Danguilan R, Gulati S, Kim S, Bavanandan S, Chiu YW, Tang SC. The burden of chronic kidney disease in Asia region: a review of the evidence, current challenges, and future directions. Kidney Research and Clinical Practice. 2024 Sep 9;44(3):411.
Mark P, Bhandari S, Shah S, Jaffer A, Mallindine C, Ashcroft R, Williams J, Bangura B, Benton S, Dunleavy A, Barratt J. Management of anaemia in chronic kidney disease: challenges and opportunities. Journal of Kidney Care. 2023 Sep 1;8(Sup5):S1-24.
Macdougall IC. Iron therapy for managing anaemia in chronic kidney disease. Current opinion in nephrology and hypertension. 2018 Sep 1;27(5):358-63.
Timofte D, Tanasescu MD, Balan DG, Tulin A, Stiru O, Vacaroiu IA, Mihai A, Popa CC, Cosconel CI, Enyedi M, Miricescu D. Management of acute intradialytic cardiovascular complications: Updated overview. Experimental and Therapeutic Medicine. 2021 Mar;21(3):282.
Alhejazi A, Alhuraiji A, Nourallah A, Alshehri A, Usman B, ElGohary G, Malhan H, Motabi I, Al Farsi10 K, Alshuaibi11 M, Diab12 M. Analysis of pharmacotherapeutic approaches.
Almalki WH, Almujri SS. Oxidative stress and senescence in aging kidneys: the protective role of SIRT1. Excli Journal. 2024 Aug 27;23:1030.
Gómez-Ramírez S, Brilli E, Tarantino G, Girelli D, Muñoz M. Sucrosomial® iron: an updated review of its clinical efficacy for the treatment of iron deficiency. Pharmaceuticals. 2023 Jun 6;16(6):847.
Chen FY, Chang WC, Kao ZK, Tan AC, Li SY, Yang CY, Lin H, Lin CC. Optimizing care for chronic kidney disease: Considerations from A to Z. Journal of the Chinese Medical Association. 2025 Oct 1;88(10):738-46.
Kuragano T, Okami S, Tanaka-Mizuno S, Uenaka H, Kimura T, Ishida Y, Yoshikawa-Ryan K, James G, Hayasaki T. Anemia treatment, hemoglobin variability, and clinical events in patients with nondialysis-dependent CKD in Japan. Kidney360. 2023 Sep 1;4(9):e1223-35.
Chang JT, Lin CJ, Yeh JH, Tsai CH, Hsieh IS, Chang PY. Sex-and stage-specific predictors of anemia in chronic kidney disease: A retrospective cohort study. Journal of Clinical Medicine. 2025 Apr 29;14(9):3088.
Jawad KS. Incidence and determinants of hypertensive disorders of pregnancy in the US: hospitalization discharge rate for preeclampsia, eclampsia, and gestational hypertensions, 2016-2018.
Gordon H, Burisch J, Ellul P, Karmiris K, Katsanos K, Allocca M, Bamias G, Barreiro-de Acosta M, Braithwaite T, Greuter T, Harwood C. ECCO guidelines on extraintestinal manifestations in inflammatory bowel disease. Journal of Crohn's and Colitis. 2024 Jan 1;18(1):1-37.
Weir MR. Managing anemia across the stages of kidney disease in those hyporesponsive to erythropoiesis-stimulating agents. American Journal of Nephrology. 2021 Jul 19;52(6):450-66.
Aitken E, Anijeet H, Ashby D, Barrow W, Calder F, Dowds B, Fielding K, Gilbert J, Jones R, Karunanithy N. UK Kidney Association Clinical Practice Guideline. Vascular Access for Haemodialysis. 2023-04-05)[2028-04-05]. https://www. renal. org/guidelines. 2023.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Ebadur Rahman, Mehadi Hasan, A.F.M. Noman, Ummay Farwa Hoque, Asma Jalal Panjery, Md. Mahbubur Rahman, Rubiya Rahim, Ummay Farwa Hoque, Ummay Farwa Hoque, Tarim Mahmood
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
